Nicholas Michael Mordwinkin - 07 Jan 2024 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Reporting relationship: Chief Business Officer
Issuer ticker: KZR
Reported as of: 07 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2024, 16:56:20 UTC
Prior SEC filing: 26 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Marc Belsky, Attorney-in-Fact

Key filing fact

Nicholas Michael Mordwinkin filed Form 4 for Kezar Life Sciences, Inc. (KZR) on 09 Jan 2024.

Key facts

This page summarizes Nicholas Michael Mordwinkin's Form 4 filing for Kezar Life Sciences, Inc. (KZR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2024, 16:56.

Change

Previous filing in this sequence was filed on 26 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KZR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +275,000
Change %
Price: $0.000000
Shares after: 275,000
Date: 07 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $0.9300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One forty-eighth (1/48th) of the shares shall vest on a monthly basis commencing on January 7, 2024, subject to the Reporting Person continuing to provide service through each such date.